Cited 29 times in
Elevated serum level of interleukin-32α in the patients with myasthenia gravis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최영철 | - |
dc.date.accessioned | 2014-12-20T17:14:22Z | - |
dc.date.available | 2014-12-20T17:14:22Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0340-5354 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94220 | - |
dc.description.abstract | A new cytokine, interleukin-32 (IL-32), has been implicated in the pro-inflammatory immune responses in several autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel diseases. Myasthenia gravis (MG) is a well-characterized autoimmune disease directed at the postsynaptic acetylcholine receptor (AChR) or end plate of the neuromuscular junction. IL-32 is a cytokine that induces tumor necrosis factor (TNF)-α, IL-6, IL-1β, and chemokine. IL-6, TNF-α, and IL-2 are related to the pathogenesis and immunoregulation of MG. The gene expression of IL-32 is increased in human natural killer (NK) cells and T lymphocytes when stimulated by IL-2 or mitogen. NK cells influence the development of experimental autoimmune MG (EAMG) and possibly MG. The aim of this study was to examine whether IL-32α levels are increased in patients with MG and to investigate the relationship between IL-32α levels and disease activity in human MG. Serum IL-32α levels were significantly higher in the MG patients (p = 0.03): 460.07 ± 192.30 pg/mL in MG patients and 248.45 ± 188.42 pg/mL in the healthy control group. Although there was no significant statistical difference, serum IL-32α levels of patients with both anti-AChR binding and blocking antibodies trended to be higher than those without either antibodies (521.56 ± 212.92 pg/mL vs. 339.52 ± 182.78 pg/mL, p = 0.16). IL-32α serum levels tended to decrease with clinical improvement in generalized MG. This study suggests the possibility that IL-32 might contribute to MG pathogenesis or immunoregulation | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1865~1870 | - |
dc.relation.isPartOf | JOURNAL OF NEUROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Interleukins/blood* | - |
dc.subject.MESH | Interleukins/immunology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myasthenia Gravis/blood* | - |
dc.subject.MESH | Myasthenia Gravis/immunology | - |
dc.subject.MESH | Young Adult | - |
dc.title | Elevated serum level of interleukin-32α in the patients with myasthenia gravis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학) | - |
dc.contributor.googleauthor | Sang-Jun Na | - |
dc.contributor.googleauthor | Seon-Hwa So | - |
dc.contributor.googleauthor | Kee Ook Lee | - |
dc.contributor.googleauthor | Young-Chul Choi | - |
dc.identifier.doi | 10.1007/s00415-011-6036-7 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04116 | - |
dc.relation.journalcode | J01627 | - |
dc.identifier.eissn | 1432-1459 | - |
dc.identifier.pmid | 21487807 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00415-011-6036-7 | - |
dc.subject.keyword | Interleukin-32α (IL-32α) | - |
dc.subject.keyword | Autoimmune disorder | - |
dc.subject.keyword | Myasthenia gravis (MG) | - |
dc.subject.keyword | Natural killer cell (NK) | - |
dc.contributor.alternativeName | Choi, Young Chul | - |
dc.contributor.affiliatedAuthor | Choi, Young Chul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 258 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1865 | - |
dc.citation.endPage | 1870 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROLOGY, Vol.258(10) : 1865-1870, 2011 | - |
dc.identifier.rimsid | 27323 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.